WO2023235422A3 - Engineered chimeric fusion protein compositions and methods of use thereof - Google Patents

Engineered chimeric fusion protein compositions and methods of use thereof Download PDF

Info

Publication number
WO2023235422A3
WO2023235422A3 PCT/US2023/024049 US2023024049W WO2023235422A3 WO 2023235422 A3 WO2023235422 A3 WO 2023235422A3 US 2023024049 W US2023024049 W US 2023024049W WO 2023235422 A3 WO2023235422 A3 WO 2023235422A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fusion protein
chimeric fusion
protein compositions
engineered chimeric
Prior art date
Application number
PCT/US2023/024049
Other languages
French (fr)
Other versions
WO2023235422A2 (en
Inventor
Daniel Getts
Original Assignee
Myeloid Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myeloid Therapeutics, Inc. filed Critical Myeloid Therapeutics, Inc.
Publication of WO2023235422A2 publication Critical patent/WO2023235422A2/en
Publication of WO2023235422A3 publication Critical patent/WO2023235422A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Compositions and methods for making and using engineered myeloid cells that express a chimeric fusion protein for immunotherapy and compositions and methods for making and using engineered T cells that express a chimeric antigen receptor for immunotherapy.
PCT/US2023/024049 2022-05-31 2023-05-31 Engineered chimeric fusion protein compositions and methods of use thereof WO2023235422A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263347183P 2022-05-31 2022-05-31
US63/347,183 2022-05-31

Publications (2)

Publication Number Publication Date
WO2023235422A2 WO2023235422A2 (en) 2023-12-07
WO2023235422A3 true WO2023235422A3 (en) 2024-04-18

Family

ID=89025522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/024049 WO2023235422A2 (en) 2022-05-31 2023-05-31 Engineered chimeric fusion protein compositions and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2023235422A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210371452A1 (en) * 2015-09-21 2021-12-02 Trilink Biotechnologies, Llc Compositions and methods for synthesizing 5'-capped rnas
WO2022066757A1 (en) * 2020-09-23 2022-03-31 Myeloid Therapeutics, Inc. Improved methods and compositions for expression of nucleic acids in cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210371452A1 (en) * 2015-09-21 2021-12-02 Trilink Biotechnologies, Llc Compositions and methods for synthesizing 5'-capped rnas
WO2022066757A1 (en) * 2020-09-23 2022-03-31 Myeloid Therapeutics, Inc. Improved methods and compositions for expression of nucleic acids in cells

Also Published As

Publication number Publication date
WO2023235422A2 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
MX2021013355A (en) Engineered chimeric fusion protein compositions and methods of use thereof.
JP7404335B2 (en) Chimeric antigen receptor with BCMA specificity and its use
KR102387243B1 (en) Transgene genetic tags and methods of use
US20190321401A1 (en) T cell receptors and engineered cells expressing same
JP2019525771A (en) Programmed death 1 ligand 1 (PD-L1) binding protein and method of use thereof
US20210024630A1 (en) Guidance and navigation control proteins and method of making and using thereof
RU2017129591A (en) Mat-Guided Chimeric Antigen Receptor Systems for Sorting / Depletion of Constructed Immune Cells
US20210284729A1 (en) Genetic modified pluri- or multipotent stem cells and uses thereof
CN103476429A (en) Novel modulators and methods of use
IL258009B2 (en) T-cell receptor (tcr)-binding antibodies and uses thereof
EP3765041A4 (en) Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
CA3147903A1 (en) Chimeric antigen receptors with mage-a4 specificity and uses thereof
US20220127343A1 (en) Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using the Same
WO2022046788A3 (en) Bispecific antibody car cell immunotherapy
WO2022098905A3 (en) Engineered chimeric fusion protein compositions and methods of use thereof
WO2023235422A3 (en) Engineered chimeric fusion protein compositions and methods of use thereof
EP3146040A1 (en) Method for producing antibodies using ovine b-cells and uses thereof
WO2023240212A3 (en) Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2024046468A1 (en) Fusion proteins targeting lysosomal degradation pathway
US20240033356A1 (en) Chimeric antigen receptor t cell and method
EP3924372A4 (en) Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
Segués Cisteró Antibody-based approaches to modulate immune response
MX2023008935A (en) Self-polarizing immune cells.
WO2023225059A3 (en) Systems of engineered receptors targeting psma and ca9
WO2023218046A1 (en) Binding agents capable of binding to cd27 in combination therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23816707

Country of ref document: EP

Kind code of ref document: A2